CRL

357.27

3.45% 11.90

Pre-mercato: 359.98 2.71 +0.76%

Charles River Laboratories International Inc (CRL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$345.37

Aprire:

$347.59

Volume 24 ore:

1.18M

Relative Volume:

0.94

Capitalizzazione di mercato:

$17.06B

Reddito:

$4.03B

Utile/perdita netta:

$-182.84M

Rapporto P/E:

-95.01

EPS:

-3.7603

Flusso di cassa netto:

$391.29M

1 W Prestazione:

+13.26%

1M Prestazione:

+22.00%

6M Prestazione:

+108.65%

1 anno Prestazione:

+82.95%

Intervallo 1D:

$0.00

Intervallo di 1 settimana:

$313.83

$357.77

Portata 52W:

$146.19

$357.77

Charles River Laboratories International Inc Stock (CRL) Company Profile

Nome

Charles River Laboratories International Inc

Settore

Healthcare (1053)

Industria

Diagnostics & Research (44)

Telefono

781-222-6000

Indirizzo

251 BALLARDVALE ST, WILMINGTON, MA

Dipendente

19,700

Cinguettio

@criverlabs

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, NTRA, A, IQV

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRL Charles River Laboratories International Inc	357.27	17.06B	4.03B	-182.84M	391.29M	-3.7603
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-30	Ripresa	UBS	Buy
2026-08-06	Aggiornamento	JP Morgan	Neutral → Overweight
2026-07-20	Downgrade	CLSA	Outperform → Hold
2026-06-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2026-05-29	Aggiornamento	CLSA	Hold → Outperform
2026-04-14	Iniziato	RBC Capital Mkts	Outperform
2025-12-15	Aggiornamento	BofA Securities	Neutral → Buy
2025-11-17	Aggiornamento	Argus	Hold → Buy
2025-11-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2025-10-06	Aggiornamento	William Blair	Mkt Perform → Outperform
2025-10-02	Aggiornamento	Barclays	Equal Weight → Overweight
2025-09-09	Aggiornamento	Jefferies	Hold → Buy
2025-07-09	Aggiornamento	Citigroup	Neutral → Buy
2025-05-23	Aggiornamento	Redburn Atlantic	Neutral → Buy
2025-05-14	Aggiornamento	TD Cowen	Hold → Buy
2025-05-08	Aggiornamento	Evercore ISI	In-line → Outperform
2025-03-21	Downgrade	Goldman	Buy → Neutral
2025-03-04	Aggiornamento	Citigroup	Sell → Neutral
2025-03-03	Aggiornamento	Redburn Atlantic	Sell → Neutral
2025-01-22	Downgrade	William Blair	Outperform → Mkt Perform
2025-01-17	Downgrade	UBS	Buy → Neutral
2024-11-18	Downgrade	CLSA	Hold → Underperform
2024-11-07	Aggiornamento	CLSA	Underperform → Hold
2024-10-23	Iniziato	CLSA	Underperform
2024-10-14	Iniziato	Redburn Atlantic	Sell
2024-10-07	Downgrade	Evercore ISI	Outperform → In-line
2024-10-02	Downgrade	BofA Securities	Buy → Neutral
2024-10-01	Downgrade	Citigroup	Neutral → Sell
2024-08-08	Downgrade	JP Morgan	Overweight → Neutral
2024-08-08	Downgrade	Robert W. Baird	Outperform → Neutral
2024-06-28	Downgrade	Argus	Buy → Hold
2024-06-07	Iniziato	Mizuho	Neutral
2024-06-06	Iniziato	Goldman	Buy
2024-02-15	Downgrade	Guggenheim	Buy → Neutral
2023-09-13	Iniziato	TD Cowen	Market Perform
2023-07-10	Downgrade	Citigroup	Buy → Neutral
2023-02-23	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-12	Downgrade	Jefferies	Buy → Hold
2022-09-30	Aggiornamento	Jefferies	Hold → Buy
2022-08-25	Iniziato	Credit Suisse	Outperform
2022-08-04	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Iniziato	Guggenheim	Neutral
2022-04-25	Downgrade	Jefferies	Buy → Hold
2022-04-07	Iniziato	Stephens	Overweight
2022-02-17	Reiterato	BofA Securities	Buy
2022-02-17	Aggiornamento	Citigroup	Neutral → Buy
2022-02-17	Reiterato	Deutsche Bank	Buy
2022-02-17	Reiterato	Morgan Stanley	Overweight
2022-02-17	Reiterato	UBS	Buy
2021-08-05	Ripresa	Credit Suisse	Neutral
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-09-10	Aggiornamento	Jefferies	Hold → Buy
2020-07-01	Aggiornamento	BofA Securities	Neutral → Buy
2020-05-13	Aggiornamento	UBS	Neutral → Buy
2020-04-21	Downgrade	Jefferies	Buy → Hold
2020-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Iniziato	Deutsche Bank	Buy
2020-02-18	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2020-01-10	Aggiornamento	Goldman	Neutral → Buy
2020-01-08	Iniziato	Wells Fargo	Overweight
2020-01-07	Iniziato	Citigroup	Buy
2019-10-18	Downgrade	BofA/Merrill	Buy → Neutral
2019-06-10	Iniziato	SVB Leerink	Outperform
2019-04-30	Ripresa	Evercore ISI	Outperform
2018-12-14	Iniziato	Deutsche Bank	Buy
2018-10-09	Iniziato	UBS	Neutral
2018-08-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2018-07-17	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Aggiornamento	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Aggiornamento	SunTrust	Hold → Buy

Mostra tutto

Charles River Laboratories International Inc Borsa (CRL) Ultime notizie

Oct 26, 2026

Charles River Laboratories’ Q3 2026 Earnings: What to Expect - Yahoo Finance

Oct 26, 2026

Oct 25, 2026

Charles River Laboratories International (CRL) Has Fresh Attention, But What Is Behind It? - Simply Wall Street

Oct 25, 2026

Oct 23, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 23, 2026

Charles River Laboratories International, Inc. Estimates – NYSE:CRL - TradingView

Oct 23, 2026

Oct 22, 2026

Charles River Laboratories (CRL) Partners with FDA and Labcorp t - GuruFocus

Oct 22, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 22, 2026

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Finviz

Oct 22, 2026

Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 - Yahoo Finance

Oct 22, 2026

Oct 21, 2026

$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today - Benzinga

Oct 21, 2026

Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype - Timothy Sykes

Oct 21, 2026

Charles River Laboratories International Jumps 7.3% in Broad Rally - AlphaStreet

Oct 21, 2026

Charles River Labs Stock Jumps As Street Hikes Targets - StocksToTrade

Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD - Investing.com

Oct 21, 2026

Charles River Laboratories stock hits 52-week high at 333.31 USD By Investing.com - Investing.com South Africa

Oct 21, 2026

Oct 20, 2026

Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued - GuruFocus

Oct 20, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 20, 2026

Dilution adjustment of Charles River Laboratories International, Inc. – XETR:RV6 - TradingView

Oct 20, 2026

Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00 - ad-hoc-news.de

Oct 20, 2026

AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects - GuruFocus

Oct 20, 2026

Citrini Bets on Life Sciences Stocks After Claude AI Drug Study - Bloomberg.com

Oct 20, 2026

Oct 17, 2026

Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus - Simply Wall Street

Oct 17, 2026